AMGEN INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 271 USD | +0.61% |
|
+0.83% | -5.85% |
| 05:03pm | Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe | MT |
| 03:38pm | Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza | DJ |
Presenter SpeechGeoffrey Meacham (Analysts)Excellent. Welcome to the BofA London Healthcare Co...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
269.4
USD
Average target price
300.3
USD
Spread / Average Target
+11.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.85% | 144B | |
| +25.86% | 653B | |
| +27.00% | 556B | |
| -6.53% | 354B | |
| +20.57% | 331B | |
| +2.97% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -11.38% | 143B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Transcript : Amgen Inc. Presents at BofA Securities Global Healthcare Conference 2022, Sep-15-2022 08
